Plasmin treatment accelerates vascular endothelial growth factor clearance from rabbit eyes

Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6162-7. doi: 10.1167/iovs.10-6396.

Abstract

Purpose: To investigate the clearance of vascular endothelial growth factor (VEGF) after the induction of posterior vitreous detachment by plasmin and/or SF(6).

Methods: The study design included four groups of rabbits: group 1 received an intravitreal injection of plasmin and SF(6) in the right eye, group 2 received an intravitreal injection of plasmin in the right eye, group 3 received an intravitreal injection of SF(6) in the right eye, and group 4 received an intravitreal injection of balanced salt solution in the right eye. Intravitreal injection of human VEGF (50 μL, 10 ng/μL) was performed in study eyes and control eyes 1 month after plasmin and/or SF(6) injection. Serum and vitreous samples were collected on days 1, 3, and 7 after VEGF injection to determine the serum and vitreous concentrations of VEGF.

Results: One day after VEGF injection, residual human VEGF concentration in the vitreous cavity was significantly lower in the plasmin- and SF(6)-treated eyes (group 1) and the plasmin-treated eyes (group 2) when compared with the control eyes (group 4) (P = 0.047 and 0.027, respectively). Three days after VEGF injection, the residual VEGF concentration in the vitreous cavity was still significantly lower in the plasmin- and SF(6)-treated eyes (group 1) when compared with the control eyes (group 4) (P = 0.025).

Conclusions: Eyes treated with plasmin exhibit a more rapid clearance of exogenous VEGF than control eyes. This finding suggests a novel treatment for retinopathies associated with vitreous traction and VEGF elevation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Combinations
  • Electroretinography
  • Enzyme-Linked Immunosorbent Assay
  • Fibrinolysin / pharmacology*
  • Intravitreal Injections
  • Microscopy, Electron, Scanning
  • Rabbits
  • Sulfur Hexafluoride / pharmacology*
  • Vascular Endothelial Growth Factor A / pharmacokinetics*
  • Vitreous Body / drug effects
  • Vitreous Body / metabolism*
  • Vitreous Detachment / chemically induced
  • Vitreous Detachment / metabolism*

Substances

  • Drug Combinations
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Fibrinolysin
  • Sulfur Hexafluoride